I've only looked at the quarterly superficially, but the main thing I picked out was that they spend 800k on R&D last quarter and that was upping to 1.6m this quarter. We know there are a few things they're busting money on: toxicology and manufacturing in particular. I could imagine that they'd need to spend money on preliminaries for P3. But I view the upscaling of R&D spending ss a positive.
Blockbuster deals aside, the next ann I'd like to see would be one showing that all the critical path activities towards P3 were on track. The manufacturing optimisation has been going on for some time, I'd guess scaling up is proving non trivial. The question is whether they could get a trial started by some time in 2018. They did a really good job of getting the P2b trial done fast, but at the risk of sounding obvious it's better to do things properly rather than quickly.
NEU Price at posting:
11.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)